Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | RAB9A | P51151 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | SMO | Q99835 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238371 | 0.91 | MAPT (1.00) | MAPTRAB9ANPC1HDAC1HDAC8 | |
| SCHEMBL10238305 | 0.88 | KCNK9 (0.69) | MAPTRAB9ANPC1HDAC1HDAC8 | |
| SCHEMBL3783679 | 0.87 | GRM4 (0.79) | MAPTRAB9ANPC1GRM4MEN1 | |
| SCHEMBL10238385 | 0.87 | MEN1 (0.70) | MAPTRAB9ANPC1MEN1KMT2A | |
| SCHEMBL403184 | 0.87 | KCNQ3 (0.67) | MAPTRAB9ANPC1HDAC1HDAC8 | |
| SCHEMBL10238306 | 0.87 | MAPT (0.65) | MAPTRAB9ANPC1HDAC1HDAC8 | |
| SCHEMBL30369807 | 0.86 | NPC1 (1.00) | MAPTRAB9ANPC1GRM4MEN1 | |
| SCHEMBL4254257 | 0.86 | NPC1 (1.00) | MAPTRAB9ANPC1GRM4MEN1 | |
| SCHEMBL8819672 | 0.85 | MEN1 (0.82) | MAPTRAB9ANPC1HDAC1HDAC8 | |
| SCHEMBL6676301 | 0.84 | MAPK14 (0.77) | MAPTRAB9ANPC1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1359371-A | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRA ZENECA LTD (SE) | 2002-07-17 | — | — | CN | claimed |
| EP-1077930-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059960-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | claimed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| CN-1188389-C | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRA ZENECA LTD (SE) | 2005-02-09 | — | — | CN | disclosed |
| EP-1077930-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| US-6465455-B1 | TUMOUR NECROSIS FACTOR AND INTERLEUKIN FAMILY INHIBITORS; INHIBITION OF ENZYME P38 KINASE; INFLAMMATION, IMMUNO-REGULATION, ALLERGIES | ASTRAZENECA AB (SE) | 2002-10-15 | — | — | US | disclosed |
| CN-1359371-A | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRA ZENECA LTD (SE) | 2002-07-17 | — | — | CN | disclosed |
| EP-1077930-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059960-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MAPT 3312/4885RAB9A 1357/4885NPC1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.